HC Wainwright cut shares of G1 Therapeutics (NASDAQ:GTHX – Free Report) from a strong-buy rating to a hold rating in a report published on Thursday morning, Zacks.com reports.
GTHX has been the subject of several other research reports. Needham & Company LLC restated a hold rating on shares of G1 Therapeutics in a report on Wednesday, August 7th. Wedbush cut shares of G1 Therapeutics from a strong-buy rating to a hold rating in a research report on Wednesday, August 7th.
Get Our Latest Report on G1 Therapeutics
G1 Therapeutics Stock Performance
G1 Therapeutics (NASDAQ:GTHX – Get Free Report) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.10) EPS for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.07. The company had revenue of $16.55 million for the quarter, compared to analyst estimates of $15.88 million. G1 Therapeutics had a negative return on equity of 74.75% and a negative net margin of 36.40%. As a group, research analysts anticipate that G1 Therapeutics will post -0.5 EPS for the current fiscal year.
Hedge Funds Weigh In On G1 Therapeutics
A number of large investors have recently made changes to their positions in GTHX. Financial Advocates Investment Management bought a new position in G1 Therapeutics during the fourth quarter worth about $39,000. SG Americas Securities LLC acquired a new stake in shares of G1 Therapeutics in the first quarter valued at approximately $58,000. Los Angeles Capital Management LLC acquired a new stake in G1 Therapeutics during the second quarter worth approximately $48,000. Capstone Investment Advisors LLC acquired a new stake in G1 Therapeutics during the fourth quarter worth approximately $76,000. Finally, Jump Financial LLC bought a new position in G1 Therapeutics during the 4th quarter worth $105,000. Institutional investors own 24.21% of the company’s stock.
G1 Therapeutics Company Profile
G1 Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer.
Recommended Stories
- Five stocks we like better than G1 Therapeutics
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Why Wall Street Analysts Raised Price Targets for Suncor Stock
- What is a Death Cross in Stocks?
- Is Super Micro Computer a Buy After Shares Sink 20% on Earnings?
- What is the Nikkei 225 index?
- MarketBeat Week in Review – 8/5 – 8/9
Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.